Telomere and Telomerase-Associated Proteins in Endometrial Carcinogenesis and Cancer-Associated Survival

Lucy Button 1, Bryony Rogers 1, Emily Thomas 1, Alice Bradfield 2, Rafah Alnafakh 1, Josephine Drury 1* and Dharani K. Hapangama 1,2,*

Abstract: Risk of relapse of endometrial cancer (EC) after surgical treatment is 13% and recurrent disease carries a poor prognosis. Research into prognostic indicators is essential to improve EC management and outcome. “Immortality” of most cancer cells is dependent on telomerase, but the role of associated proteins in the endometrium is poorly understood. The Cancer Genome Atlas data highlighted telomere/telomerase associated genes (TTAGs) with prognostic relevance in the endometrium, and a recent in silico study identified a group of TTAGs and proteins as key regulators within a network of dysregulated genes in EC. We characterise relevant telomere/telomerase associated proteins (TTAPs) NOP10, NHP2, NOP56, TERF1, TERF2 and TERF2IP in the endometrium using quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC). qPCR data demonstrated altered expression of multiple TTAPs; specifically, increased NOP10 (p = 0.03) and reduced NHP2 (p = 0.01), TERF2 (p = 0.01) and TERF2IP (p < 0.003) in EC relative to post-menopausal endometrium. Notably, we report reduced NHP2 in EC compared to post-menopausal endometrium in qPCR and IHC (p = 0.0001) data; with survival analysis indicating high immunoscore is favourable in EC (p = 0.0006). Our findings indicate a potential prognostic role for TTAPs in EC, particularly NHP2. Further evaluation of the prognostic and functional role of the examined TTAPs is warranted to develop novel treatment strategies.

Keywords: telomere; telomerase; protein; endometrium; endometrial cancer; qPCR; immunohistochemistry

1. Introduction

Endometrial cancer (EC) is the most common gynaecological malignancy [1], responsible for 2500 deaths in the UK in 2018 alone. Despite improvement in 5-year survival over the last 40 years to 75.6% (2013–2017) [2], the risk of recurrence in surgically treated EC is 13% [3]. Unfortunately, the prognosis for recurrent disease is particularly poor; therefore, research into prognostic markers is essential to improve clinical outcomes by informing management decisions [4].

Telomeres cap the terminal ends of eukaryotic chromosomes and are composed of tandem repeats of the nucleotide sequence TTAGGG [5], which are essential for genomic stability. The telomere DNA sequence has a guanosine rich 3′ overhang which may also act to protect the chromosome from degradation [6,7] (Figure 1). Telomeres are transcribed as long non-coding RNAs called TERRAs (TELomeric Repeat containing RNA), which participate in a variety of cellular regulatory functions [8,9]. With normal cell division, there is loss of telomeric DNA and attrition of the telomere, resulting in an end replication problem [10]. Once the telomere is at a critical length, there is cell cycle arrest through initiating either cellular senescence or apoptosis pathways [11]. Telomeric shortening and
dysregulation are implicated with ageing and disease, including cancer [12], thus telomere maintenance (TM) is an essential cellular function.

The specialised ribonucleoprotein complex, telomerase, maintains telomeres through elongation of the single telomeric DNA strand using an RNA template specific to the 3' sequence to add G-rich repeats [13,14]. Telomerase is a holoenzyme consisting of primary components: human reverse transcriptase (hTERT, the catalytic unit), and the integral human telomerase RNA component (hTERC) [14,15]. hTERC harbours an H/ACA domain essential for 3' end processing and accumulation of hTERC as well as telomerase activity [16]. This H/ACA motif is responsible for post-transcriptional modifications, and is shared with small nucleolar and small Cajal body RNAs [17]. The motif associates with four core preserved proteins: dyskerin (DKC1), NHP2, NOP10 and GAR1; forming small nucleolar ribonucleoproteins (snoRNP) [17–19] (Figure 1). These snoRNP's are responsible for the stability and accumulation of telomerase RNA, which is vital for normal telomerase activity [20]. NOP56 is another snoRNP, which forms a component of the Box C/D snoRNP complex [21]. It is thought to be required for protein synthesis and cellular division as it is involved in pre-rRNA processing and ribosome biogenesis, and is rate limiting for cell proliferation [22–24]. NOP56 is indirectly associated with telomerase activity, as it interacts with multiple components of the telomerase complex, including DKC1 and NHP2 [25,26]. Furthermore, hypomorphic mutations within the NOP56 gene may elongate telomeres [27].

The telosome or shelterin, is another protein complex directly associated with the telomere, with a high specificity for the telomeric sequence. The complex consists of six telomere specific proteins; the three subunits Telomeric Repeat factor 1 and 2 (TERF1, TERF2) and Protection of Telomeres 1 (POT1) bind directly to the chromosomal end. Three additional proteins Repressor/Activator Protein 1 (TERF2IP), TERF1-Interacting Nuclear Protein 2 (TIN2) and Tripeptidyl Peptidase 1 (TPP1) interconnect these subunits. Shel-
terin acts to protect chromosomes from fatal end to end or sister chromatid fusion and deterioration [28] and regulates telomere length through its action on telomerase. TERF2 encourages the formation of telomerase or t-loops, where the terminus of telomeric DNA is ‘tucked’ away. This protects normal linear DNA at the ends of the chromosomes, making them inaccessible, even to telomerase [29]. Consequently, this prevents chromosomal ends from being detected as a double strand break, averting a DNA damage response (DDR) [6], while also suppressing telomerase activity, thus regulating telomere length [29]. TERF1 also regulates telomerase activity through a negative feedback mechanism, stabilising telomere length [30,31].

Telomerase activity is essential for the maintenance of critical telomere length, enabling cell replicative immortality, one of the hallmarks of cancer [32]. Approximately 85% of human cancers achieve indefinite cell proliferation and avoidance of telomeric shortening through increased telomerase activity. In the absence of telomerase, the remainder achieve immortalisation through a different mechanism; the alternative lengthening of telomeres (ALT); considered to primarily involve DNA recombination [33]. Telomerase activity is usually undetectable in normal somatic cells; in contrast to the functionally significant levels observed in approximately 90% of immortalised cells, including cancer cells [32,34]. Nevertheless, the human endometrium is a dynamic somatic organ with a unique ability to undergo monthly regeneration and proliferation [35–37]. Previous research has demonstrated high telomerase activity in the premenopausal endometrium, with a transition to low or undetectable levels in the postmenopausal endometrium [36,38,39]. Despite unique endometrial telomerase biology, there is reactivation of telomerase activity from the postmenopausal state to EC [28,29,35,40]. Hence, telomerase must factor in the malignant transformation of the endometrium. Evidently, telomere and telomerase associated proteins (TTAPs) are essential for TM, which is central to cancer cell proliferation. Therefore, these proteins may hold clinical significance in EC.

We hypothesised that TTAPs have a role in the human endometrium and may hold clinical relevance in EC. The specific proteins under examination were selected considering the publicly available survival analysis data of The Cancer Genome Atlas (TCGA) EC mRNA sequencing dataset from the Human Protein Atlas, which identified genes with prognostic relevance (Supplementary Figure S1) [41] and our previously published in silico study [42]. In this ex vivo study, we tested this hypothesis by studying the levels of the genes NOP10, NHP2, NOP56, TERF1, TERF2 and TERF2IP and the proteins they encode, in the healthy human endometrium and in a cohort of EC samples. Subsequently, we assessed the prognostic relevance of the protein immunoscores.

2. Results
2.1. Patient Population and Demographic Details

A total of 103 patients were included, with 13 pre-menopausal, 27 post-menopausal and 63 with endometrial cancer. Biopsies were obtained for quantitative polymerase chain reaction (qPCR) and/or immunohistochemical analysis. See Table 1 (and Supplementary Table S1) for patient demographics. Within the cohort, previous tamoxifen use was noted in two post-menopausal patients (7%) and two carcinosarcoma samples (13%), in addition to prior use of anastrazole in one (5%) Grade 3 endometrioid cancer patient.
### Table 1. Patient cohort demographic details.

| Patient Group | Number of Patients | Age Median (Range) | BMI Median (Range) | Parity Median (Range) | Smokers Number (% | HRT Number (%) | Death Number (%) | Recurrence Number (%) |
|---------------|--------------------|--------------------|--------------------|-----------------------|-------------------|-----------------|---------------------|-----------------------|
| Pre-Menopausal| 13                 | 41 (32–57)         | 26.7 (18.9–40.5)   | 2 (1–6)               | 6 (46%)           | n/a             | n/a                 | n/a                   |
| Post-Menopausal| 27                | 62 (51–85)         | 24.9 (17.9–39.6)   | 3 (0–5)               | 6 (22%)           | 1 (4%)          | n/a                 | n/a                   |
| Cancer        | 63                 | 68 (37–78)         | 28.75 (20.2–54.4)  | 2 (0–7)               | 3 (5%)            | 7 (11%)         | 30 (48%)            | 30 (48%)              |

#### 2.2. Rationale for Selecting Specific TTAPs

In this study, the specific proteins under examination were selected initially following survival analysis of EC mRNA sequencing dataset of TCGA from the Human Protein Atlas, which identified genes with prognostic relevance (Supplementary Figure S1) [41,43]. TCGA dataset revealed the encoding genes for TTAPs dyskerin, NOP10, NHP2 and wider associated protein NOP56 to have prognostic relevance in EC (see Supplementary Figure S1) [41,43]. The expression of the DKC1 gene and protein product dyskerin, have already been thoroughly investigated in the endometrium [44]. The remaining H/ACA snoRNP, GAR1, though seen to be highly expressed, was not prognostic in the endometrium [41,45]; therefore, it was not examined.

Further proteins under examination were selected following our previously published detailed in silico study investigating the role of telomere and telomerase associated genes and proteins in EC. Telomerase associated protein NHP2 and wider associated protein NOP56 were identified as key regulatory genes within a network of genes dysregulated in stage I and IV EC [42], (Supplementary Figure S2 [46]) therefore both were examined.

TERRAs have been seen to be significantly altered in EC [9] and shelterin proteins TERF1/2 are known to interact with TERRA [8]. Thus, we also selected shelterin proteins TERF1/2 for examination. The third shelterin subunit, POT1 was not included as it has already been examined in the endometrium [47]. TERF2IP was included in our study as it binds to TERF2, therefore is structurally relevant [48]. TERF1/2 and TERF2IP proteins which were non-prognostic according to TCGA data, they were also included for study validation. Supplementary Figure S3 demonstrates a protein–protein interaction network diagram created using STRING [25,46]; to explore and identify the predicted functional interaction networks between the proteins of interest.

#### 2.3. qPCR Data

In our independent patient sample set, initially, we determined mRNA expression levels of genes encoding the TTAPs of interest in PM and cancer samples. Rationale for this qPCR analysis was to confirm whether similar differences observed in the TCGA cohort was present in our patient cohort, prior to investigating the protein products of the selected TTAP genes with immunohistochemistry (IHC). We found a statistically significant increase in NOP10 mRNA expression in cancer tissue relative to healthy post-menopausal endometrium ($p=0.03$) (Figure 2). NHP2 ($p=0.01$), TERF2 ($p=0.01$) and TERF2IP ($p<0.003$) mRNA expression was significantly reduced in EC when compared to post-menopausal endometrium. There was no significant alteration in mRNA expression levels for NOP56 or TERF1.
Figure 2. qPCR data for selected telomere and telomerase associated transcripts NOP10, NHP2, NOP56, TERF1, TERF2 and TERF2IP. Individual points shown are the mean of technical triplicates, with the median indicated by the line. Post-menopausal, \( n = 6 \); Cancer, \( n = 21 \) for all genes examined.

2.4. Characterisation of Telomere and Telomerase Associated Protein Expression

The presence of each protein of interest was visualised at a cellular level using IHC, and immunostaining was semi-quantified using a modified Quickscore in our independent patient sample set. Nuclear staining was assessed in glandular epithelial cells from all endometrial tissue samples. Immunoscores for each protein were compared between healthy pre-menopausal and post-menopausal endometrium and cancer samples (Figure 3); representative micrographs for all studied proteins are illustrated in Figure 4.

We found a statistically significant reduction in NHP2 immunoscores in EC samples relative to healthy post-menopausal endometrium (\( p < 0.0001 \)) (Figure 3). Immunohistochemical staining demonstrated a statistically significant difference in the abundance of TERF1, with reduced Quickscores in post-menopausal (\( p < 0.006 \)) and EC (\( p = 0.0006 \)) tissues relative to healthy pre-menopausal samples. A statistically significant loss of TERF2 and TERF2IP immunostaining was also identified in EC samples when compared to post-menopausal samples (\( p < 0.004 \) and \( p < 0.0001 \), respectively).

No significant difference was observed in the abundance of NOP10 or NOP56 between pre-menopausal, post-menopausal and EC samples (Figure 3).
2.5. Survival Analysis

We performed survival analysis with corresponding survival curves using an optimal cut off for each of the protein IHC Quickscores with clinical outcomes from our local patient cohort as displayed in Figure 5. Survival analysis demonstrated a significant difference between high and low Quickscores of NHP2 ($p = 0.0006$) and high Quickscore of NHP2 was favourable (HR 4.38, 95% CI 1.89–10.16). In our patient cohort, a significant difference was observed in survival when comparing the low and high abundance of NOP56 ($p = 0.02$), where a high abundance of NOP56 was unfavourable (HR 0.35, 95% CI 0.14–0.86). We found no significant difference in survival curves for NOP10, TERF1, TERF2 or TERF2IP.

Figure 3. Scatterplots to show Quickscores for NOP10, NHP2, NOP56, TERF1, TERF2 and TERF2IP. Line indicates median. NOP10 pre-menopausal $n = 12$, post-menopausal $n = 11$ (pre-menopausal vs. postmenopausal $p = 0.059$), cancer $n = 39$; NHP2 pre-menopausal $n = 12$, post-menopausal $n = 11$, cancer $n = 41$; NOP56 pre-menopausal $n = 7$, post-menopausal $n = 12$, cancer $n = 43$; TERF1 pre-menopausal $n = 6$, post-menopausal $n = 10$, cancer $n = 30$; TERF2 pre-menopausal $n = 12$, post-menopausal $n = 16$, cancer $n = 51$; TERF2IP pre-menopausal $n = 12$, post-menopausal $n = 17$, cancer $n = 57$.
Figure 4. Representative photomicrographs of NOP10, NHP2, NOP56, TERF1, TERF2 and TERF2IP immunohistochemical staining in human endometrial samples from pre-menopausal, post-menopausal and cancer patients. Magnification 40×, scale bar is 60 microns. Positive staining appears brown.
Figure 5. Survival curves obtained from IHC Quickscores of experimental data. Low quickscore data shown in grey, high quickscore data in black. (a) Overall survival (OS). Low NOP10 n = 15, high NOP10 n = 26, \( p = 0.56 \); low NHP2 n = 27 median survival 14 months, high NHP2 n = 12, median survival undefined, \( p = 0.0006 \); low NOP56 n = 27, median survival 30 months, high NOP56 n = 16 median survival 16 months, \( p = 0.02 \); low TERF1 n = 19, high TERF1 n = 11, \( p = 0.78 \); low TERF2 n = 41, high TERF2. n = 11, \( p = 0.97 \); low TERF2IP n = 25, high TERF2IP n = 33, \( p = 0.69 \). (b) Disease-free survival (DFS). Low NOP10 n = 15, high NOP10 n = 26, \( p = 0.8 \); low NHP2 n = 27 median DFS 11.5 months, high NHP2 n = 12, median DFS undefined, \( p < 0.005 \); low NOP56 n = 27, median DFS undefined, high NOP56 n = 16 median DFS 10 months, \( p < 0.05 \); low TERF1 n = 19, high TERF1 n = 11, \( p = 0.69 \); low TERF2 n = 41, high TERF2. n = 11, \( p = 0.96 \); low TERF2IP n = 25, high TERF2IP n = 33, \( p = 0.70 \).
2.6. Correlations

Immunoscores for the proteins of interest for the entire sample cohort were correlated with cell proliferation marker Ki67, and between each protein of interest. Semi-quantitative immunostaining data for the four steroid receptors (ERα, ERβ, PR and AR) in EC samples was correlated with Quickscores for the proteins of interest.

NHP2 ($r = -0.45, p = 0.001$) and TERF2IP ($r = -0.42, p < 0.0002$) protein levels as demonstrated using IHC immunoscores, showed a negative association with Ki67 (see Table 2).

When comparing Quickscores for proteins of interest in healthy and malignant samples (Table 3), we identified statistically significant positive correlations between NHP2 and TERF1 ($r = 0.34, p = 0.02$), NOP56 and TERF2 ($r = 0.53, p < 0.0002$), TERF1 with TERF2 ($r = 0.65, p < 0.0001$) and TERF2IP ($p = 0.002$), TERF2 and TERF2IP ($p < 0.0001$).

When correlating steroid receptor data with immunoscores for the proteins of interest in EC samples, we found a statistically significant positive correlation between PR and NHP2 ($r = 0.51, p = 0.002$) and AR with NHP2 ($r = 0.4, p = 0.025$). We also found a negative association between ERα and NOP56 ($r = -0.36, p = 0.03$) and AR with NOP56 ($r = -0.41, p = 0.02$). There were no significant associations with ERβ (see Table 4).

### Table 2. Ki67 correlations with telomere and telomerase associated protein Quickscores for all samples.

| Ki67 Correlations | NOP10 | NHP2 | NOP56 | TERF1 | TERF2 | TERF2IP |
|-------------------|-------|------|-------|-------|-------|---------|
| Number            | 51    | 48   | 48    | 36    | 70    | 73      |
| Spearman r        | -0.09 | -0.45| 0.04  | -0.33 | -0.23 | -0.42   |
| 95% confidence interval | -0.36 to 0.20 | -0.66 to -0.19 | -0.25 to 0.33 | -0.60 to 0.01 | -0.45 to 0.01 | -0.60 to -0.21 |
| p value (two-tailed) | 0.54  | 0.001| 0.77  | 0.05  | 0.06  | <0.0002 |

Statistically significant results are indicated in bold text.

### Table 3. Correlations between telomere and telomerase associated protein Quickscores for all samples.

| NOP10 | NHP2 | NOP56 | TERF1 | TERF2 | TERF2IP |
|-------|------|-------|-------|-------|---------|
| r     | 0.16 | 0.24  | -0.14 | 0.15  | -0.24   |
| p     | 0.22 | 0.07  | 0.35  | 0.31  | 0.08    |
| n     | 59   | 59    | 46    | 51    | 54      |
| NHP2  |      |       |       |       |         |
| r     | 0.16 | -0.12 | 0.34  | 0.24  | 0.27    |
| p     | 0.22 | 0.39  | 0.02  | 0.11  | 0.05    |
| n     | 59   | 56    | 46    | 48    | 53      |
| NOP56 |      |       |       |       |         |
| r     | 0.24 | -0.12 |       | 0.13  | 0.53    |
| p     | 0.07 | 0.39  | 0.41  | <0.0002| 0.09    |
| n     | 59   | 56    | 43    | 46    | 52      |
| TERF1 |      |       |       |       |         |
| r     | -0.14| 0.34  | 0.13  |       | 0.65    |
| p     | 0.35 | 0.02  | 0.41  | <0.0001| 0.002   |
| n     | 46   | 46    | 43    | 36    | 38      |
| TERF2 |      |       |       |       |         |
| r     | 0.15 | 0.27  | 0.53  | 0.65  | r       |
| p     | 0.31 | 0.05  | <0.0002| 0.0001| p       |
| n     | 51   | 48    | 46    | 36    | 76      |
| TERF2IP|     |       |       |       |         |
| r    | -0.24| 0.27  | 0.24  | 0.48  | 0.46    |
| p    | 0.08 | 0.05  | 0.09  | 0.002 | <0.0001 |
| n    | 54   | 53    | 52    | 38    | 76      |

R = Spearman rank correlation, $p = 2$-tailed $p$ value, $n =$ number of pairs analysed. Statistically significant correlations highlighted in bold text.
Table 4. Steroid hormone receptor correlations with telomere and telomerase-associated protein quickscores for endometrial cancer samples.

|                      | PR  | ERα | ERβ  | AR  |
|----------------------|-----|-----|------|-----|
| **NOP10**            |     |     |      |     |
| n                    | 36  | 34  | 34   | 34  |
| Spearman r           | −0.03 | 0.25 | 0.06 | −0.08 |
| 95% confidence interval | −0.36 to 0.32 | −0.10 to 0.55 | −0.29 to 0.40 | −0.41 to 0.28 |
| p value (two-tailed) |   0.88 | 0.15 | 0.72 | 0.66 |

| **NHP2**             |     |     |      |     |
| n                    | 33  | 31  | 31   | 31  |
| Spearman r           | 0.51 | 0.09 | 0.17 | 0.40 |
| 95% confidence interval | 0.20 to 0.73 | −0.28 to 0.44 | −0.20 to 0.51 | 0.04 to 0.67 |
| p value (two-tailed) |   0.002 | 0.63 | 0.35 | 0.03 |

| **NOP56**            |     |     |      |     |
| n                    | 37  | 35  | 35   | 35  |
| Spearman r           | −0.30 | −0.36 | −0.12 | −0.41 |
| 95% confidence interval | −0.57 to 0.04 | −0.62 to −0.02 | −0.44 to 0.23 | −0.66 to −0.08 |
| p value (two-tailed) |   0.07 | 0.03 | 0.49 | 0.02 |

| **TERF1**            |     |     |      |     |
| n                    | 27  | 25  | 25   | 25  |
| Spearman r           | −0.03 | −0.02 | −0.39 | −0.10 |
| 95% confidence interval | −0.41 to 0.37 | −0.42 to 0.39 | −0.69 to 0.01 | −0.49 to 0.32 |
| p value (two-tailed) |   0.90 | 0.91 | 0.05 | 0.62 |

| **TERF2**            |     |     |      |     |
| n                    | 44  | 42  | 42   | 42  |
| Spearman r           | −0.14 | 0.01 | −0.05 | −0.07 |
| 95% confidence interval | −0.43 to 0.17 | −0.30 to 0.32 | −0.36 to 0.26 | −0.37 to 0.25 |
| p value (two-tailed) |   0.37 | 0.92 | 0.73 | 0.68 |

| **TERF2IP**          |     |     |      |     |
| n                    | 49  | 47  | 47   | 47  |
| Spearman r           | −0.03 | 0.07 | −0.18 | 0.21 |
| 95% confidence interval | −0.32 to 0.26 | −0.23 to 0.36 | −0.45 to 0.12 | −0.09 to 0.47 |
| p value (two-tailed) |   0.84 | 0.65 | 0.23 | 0.16 |

n = number of pairs analysed for each correlation. Statistically significant results are indicated in bold text.

3. Discussion

We identified altered NOP10, NHP2, TERF2 and TERF2IP mRNA levels and significantly different protein immunostaining levels for NHP2, TERF2 and TERF2IP in EC when compared with healthy post-menopausal endometrium. Both NHP2 and NOP56 protein immunoscores were associated with patient survival, suggesting a prognostic relevance. To our knowledge, this is the first study comprehensively examining and characterising the expression of six TTAPs with purported importance in the healthy and malignant endometrium. We also describe the changes in expression of these six TTAPs in endometrial carcinogenesis, and cancer associated survival.

3.1. NOP10

Expression of protein encoding gene NOP10 has been reported to be decreased in patients with chronic lymphocytic leukaemia (CLL) [49]. Conversely, our qPCR data for NOP10 demonstrated altered mRNA expression in EC with a statistically significant increase when compared to the post-menopausal endometrium. However, the differential expression of NOP10 mRNA was not associated with increased levels of endometrial NOP10 protein. We scored nuclear staining and NOP10 is expected to be nucleolar. We assessed nuclear staining because it was difficult to evaluate nucleolar staining when there was also nuclear staining present; nucleolar scoring may be more reflective of mRNA data. Elsharawy et al. examined NOP10 using IHC in breast cancer and reported a significant increase in NOP10 when assessing both nuclear and prominent nucleolar staining. High abundance of NOP10 protein whether in the nucleus or in the nucleoli demonstrated a
significant association with unfavourable characteristics including high tumour grade, thus substantiating this hypothesis for non-significance in our study [50].

Post-transcriptional regulation may also be responsible for this discordant relationship, therefore differential NOP10 mRNA expression may not manifest as variation at the functional level of the protein. Additionally, changes in NOP10 protein levels did not carry any significance for patient outcome, in contrast with TCGA RNA data [43].

3.2. NHP2

NHP2 mRNA expression decreased in EC when compared to post-menopausal endometrium. IHC data revealed a concordant, statistically significant reduction in NHP2 abundance in EC when compared to pre-menopausal and post-menopausal endometrium controls. Previous studies have explored the expression and clinical significance of NHP2 in various cancer types. NHP2 and its encoding gene have been shown to be overexpressed in gastric and colorectal cancers [51,52]. Kim et al., reported increased levels of NHP2 protein and upregulation of its encoding gene in gastric and colorectal cancer tissues [51]. Their contrasting results when compared with our findings may be due to the discrepancies in sample size reducing the generalisability of results in different populations, as well as the biological differences between different cancer types. This possibility needs to be explored further since the human endometrium has been demonstrated to have a unique telomerase biology. High telomerase activity is observed in most epithelial cancers; however, the benign endometrium also demonstrates high telomerase activity [36]. Thus, endometrial carcinogenesis may result in altered function and subsequently altered levels of its associated proteins relative comparison to other malignancies; further functional analysis is thus warranted to explore this. Witkowska et al. identified significant upregulation of NHP2, specifically in high stage colonic cancer. Thus, an explanation for their contradicting results may be the selection of samples, with a high clinical stage presenting a confounding variable. Additionally, the use of microarray, a different technique to analyse gene expression, may also affect results.

EC is typically a disease of the post-menopausal endometrium with 90% of cases occurring in women over the age of 50 [53], thus establishing healthy post-menopausal samples as the most appropriate control. The reduction observed in NHP2 mRNA expression and protein product NHP2 in EC relative to post-menopausal samples is our most notable finding; these results suggest loss of NHP2 is a malignant transformation, indicating NHP2 may have a prospective role as a biomarker.

Further to this, our survival analysis suggests highly abundant NHP2 is favourable for patient outcome in EC. Thus, NHP2 may also have potential as a prognostic indicator, although further research is warranted. Conversely, TCGA data previously demonstrated that high expression of NHP2 is unfavourable [43]. The disagreement in results may be attributable to contrasting techniques for analysis (TCGA survival analyses use RNA sequencing data), the inclusion of varied cancer types within this study and the use of different ‘normal controls’ in each study. As previously described by Alnafakh et al., TCGA utilises ‘normal’ tissue within 2 cm from the tumour for comparison, in contrast to the external healthy controls within this study. It is vital to consider that endometrioid and serous ECs within the TCGA data set are likely to have originated from a background of endometrial hyperplasia or endometrial intraepithelial neoplasia. Consequently, the control samples obtained from tissue adjacent to the tumour site (considered to be normal endometrium for comparison in TCGA data), may include areas of endometrial hyperplasia or endometrial intraepithelial neoplasia [44]. Additionally, we consider our data to be more generalizable, with the use of histologically confirmed external healthy controls from a well-characterised population.

Furthermore, we propose NHP2 as a promising potential biomarker and possible prognostic indicator, utilising an affordable and accessible technique of immunohistochemical staining. It is important to consider that although a greater abundance of immunologically reactive NHP2 protein is seen within healthy tissues, this protein may not be functional;
this can only be determined by functional assays. In this study, we report a statistically significant negative association between NHP2 and cell proliferation marker Ki67, indicating NHP2 loss may occur due to sustained cell proliferation signalling, one of the hallmarks of cancer [32].

The loss of NHP2 observed in EC is interesting when considered in the context of our current understanding of endometrial telomerase biology. Telomerase activity is reported to be at functionally significant levels in the pre-menopausal endometrium [38,39] and EC [28,36]; therefore, a similar expression of TTAPs in EC is expected. Nevertheless, NHP2 demonstrates the contrary, indicating there may be protein encoding gene dysregulation due to disease pathogenesis. Gene expressional analysis is necessary to validate this conclusion.

Estrogen receptor (ER) and progesterone receptor (PR) are the most validated prognostic biomarkers for EC; the loss of both hormone receptors is a predictor of poor prognosis [54,55]. Our data indicate a statistically significant positive association between NHP2 and PR, prompting further investigation into its role in improving the performance of known prognostic indicators. Progesterone inhibits telomerase activity and hTERT expression in the endometrium, and expression of PR has been positively correlated with a good prognosis of EC. ECs regress in response to progesterone, therefore progesterone is used to treat advanced ECs. Telomerase is an indirect downstream target of progesterone [36]. The positive relationship identified between PR and telomerase associated protein NHP2 may imply a greater abundance of NHP2 is associated with a better prognosis, corroborating our survival analysis.

3.3. NOP56

NOP56 has been shown to be upregulated in acute myeloid leukaemia and may also be associated with poorer outcome [56]. It has also been identified as a marker of unfavourable prognosis in liver cancer, renal cancer and melanoma [57,58]. NOP56 is less directly associated with telomerase as it interacts with DKC1 and NOP10, and it is predicted to bind to NHP2 [59–62]. We found no significant difference in NOP56 mRNA expression or protein abundance between healthy and malignant endometrium; however, survival analysis indicates high abundance is unfavourable for clinical outcome in EC, in keeping with findings from previous studies in other malignancies [57,58]. NOP56 IHC EC data also showed a negative correlation with steroid receptors ERα and AR, indicating possible significance prognostically, warranting further exploration.

3.4. TERF1

Expression of TERF1 has previously been shown to have significant overexpression or downregulation, dependent on cancer type [63–67]. Interestingly, a study by Bejarano et al. has also validated TERF1 inhibition in glioblastoma as an effective therapeutic strategy [67]. In the endometrium, we report no significant difference in the expression of TERF1 mRNA or protein levels when comparing post-menopausal endometrium and EC. We identified changes in protein levels when comparing pre-menopausal samples to post-menopausal and EC samples; the significance of this loss of protein in EC is unknown. Since high telomerase activity is a feature of endometrial cancer [28,36], an increased abundance of relevant proteins is anticipated. However, TERF1 is associated with the telomere complex and the protection of telomere length. Despite high telomerase activity, EC cells have been reported to possess shorter telomeres [9] and since TERF1 imposes a negative feedback on telomerase activity [30,31], we can speculate that the observed loss of this protein may be beneficial for maintaining high telomerase activity in EC cells. Survival analyses for TERF1 data were non-significant, and predictable positive correlations were seen with structurally related proteins TERF2 and TERF2IP.
3.5. TERF2 and TER2IP

Previous reports have implied abnormally high or low expression of TERF2 may lead to chromosomal instability and induce fatal tumour changes [68]. We observed loss of TERF2 mRNA and protein levels in EC relative to postmenopausal endometrium, however, TERF2 levels did not carry clinical significance in survival analysis. TERF2 immunoscores positively correlated with TER2IP, likely due to their structural relationship [28]. Loss of TERF2 may make the telomeres accessible to telomerase, facilitating telomerase activity at the telomere site [29]. TERF2 may hold potential as a biomarker in EC, as reduced protein levels may be attributed to malignant transformation; nevertheless, this needs further exploration. Upregulation of TERF2 has been previously observed in hepatocellular carcinoma [69] and cervical cancer where it has a positive impact on survival in patients with advanced stage cancer [70].

Similarly, to structurally related protein TERF2, TERF2IP mRNA expression and proteins levels are reduced in EC relative to healthy postmenopausal endometrium. TERF2IP EC immunoscores had a negative association with Ki67 thus we anticipated that to indicate functional or prognostic relevance, yet, no significant separation was observed in survival analyses comparing high vs. low protein levels. Contrastingly, TERF2IP expression has previously been reported to be significantly higher in breast tumour tissues relative to adjacent non-tumour tissues [71], and highly expressed in colorectal cancer tissues; with high expression correlated with poor prognosis and distant metastasis in colorectal cancer [72]. The alteration in mRNA and protein levels in EC relative to postmenopausal endometrium may implicate TERF2IP as another TTAP with potential as a prognostic indicator, possibly in combination with TERF2, that we were unable to identify in our sample size, therefore further investigation is warranted.

3.6. Limitations

Limited sample size due to our modest patient cohort, pose an obstacle for drawing definitive conclusions for the proteins under examination; significant results on such a small scale may not be representative of the population. Though we thoroughly explore the presence of the selected TTAPs in healthy and malignant endometrium, we also acknowledge our methods do not assess the functionality of the proteins under examination. Consequently, we propose future research into the functional and prognostic role for the selected TTAPs. Another limitation is the use of Quicksoring; a semi-quantitative method where subjectivity may influence results. Nevertheless, a subset of samples was double-scored, and scorers met to review any discrepancies and agreed upon final values.

4. Materials and Methods

A selection of TTAPs from both the telomerase and shelterin complexes and associated proteins were chosen to examine their expression using real time quantitative reverse transcriptase PCR (qPCR) and immunohistochemistry (IHC) in endometrial biopsies obtained from women with EC and post-menopausal women with no endometrial abnormalities.

Ethical approval was granted by Liverpool and Cambridge Adult Research Ethics Committee (LREC 09/H1005/55, 11/H1005/4 and CREC 10/H0308/75) and informed written consent was obtained from all participants.

4.1. Patient Population and Sample Collection

Endometrial biopsies were obtained from women undergoing surgery in Liverpool Women’s Hospital between 2009 and 2014 [73]. Samples were divided and either (i) fixed (≥24 h in 10% (v/v) neutral buffered formalin) and paraffin embedded for immunohistochemical staining, or (ii) placed in RNALater.

Adhering to the International Federation of Gynaecology and Obstetrics guidance [20], gynaecological pathologists allocated histological descriptors for EC type and grade. Normal endometrial samples were assigned phases according to histological features and last menstrual date as described by Kamal et al. [21].
Patient clinico-pathological and demographic details were obtained by review of hospital records and clinical databases. Patients included in the study did not receive any neoadjuvant hormonal treatment, chemotherapy or radiotherapy.

4.2. qPCR

qPCR was conducted as previously described [9,44,74]. Briefly, total RNA from tissue samples and cultured cell lines were extracted using PureLink RNA mini kit (Invitrogen by ThermoFisher Scientific, Loughborough, UK) according to the manufacturer’s instructions. RNA concentration and purity was assessed spectrophotometrically.

DNA was removed using RQ1 RNase-Free DNase (Promega, Southampton, UK) followed by reverse transcription of 1 µg total RNA using iScript cDNA synthesis kit (Bio-Rad, Hertfordshire, UK), and stored at −80 °C. A no-reverse transcriptase (NRT) control was prepared with each reaction.

Gene expression was quantified by qPCR in triplicate using iTaq universal SYBR green supermix and the CFX Connect Real-Time System (Bio-Rad, Hertfordshire, UK) for the three housekeeping genes, PPIA, IPO8 and MRPL19 (Sigma Custom Products (Merck), Haverhill, Suffolk, UK) and for the genes of interest; NOP10, NHP2, NOP56, TERF1, TERF2 and TERF2IP (Bio-Rad, Hertfordshire, UK). The sequences and amplicon length of each gene used are displayed in Table 5.

Amplification was for 40 cycles of denaturation at 95 °C (5 s) and annealing/extension at 60 °C (30 s) after initialisation at 95 °C (2 min). Melt curves were obtained at the end of each run and amplification products were verified using agarose gel electrophoresis to confirm the amplicon length. Standard curves were generated for all genes using the HEK293 cell line.

Table 5. Gene Sequences and amplicon length of all genes examined, IPO8, PPIA, MRPL19, NOP10, NHP2, NOP56, TERF1, TERF2 and TERF2IP.

| Gene Name | Sequences (5′–3′)/Unique Assay ID | Amplicon Length |
|-----------|----------------------------------|----------------|
| IPO8      | Forward: AGGATCACAGGACAGCAGACGCTGCA | 102            |
|           | Reverse: AGGTGAACCGCCCTCCGTGGTTC |                |
| PPIA      | Forward: AGACAAAGTTGCTCCAAGAGAC   | 118            |
|           | Reverse: ACCACCTGACACATAAA        |                |
| MRPL19    | Forward: CAGGAAGAGGACTTGGAGCCTAC  | 137            |
|           | Reverse: GCTATCATCCAGCGGTTCCTCTA |                |
| NHP2      | qHsaCED0037860                    | 164            |
| NOP10     | qHsaCID0012562                    | 83             |
| NOP56     | qHsaCEP0025699                    | 89             |
| TERF1     | qHsaCID0022415                    | 100            |
| TERF2     | qHsaCID0015690                    | 123            |
| TERF2IP   | qHsaCID007952                     | 123            |

4.3. Immunohistochemistry

Immunohistochemistry was performed as previously described [75–77]. Before immunostaining, 3 µm, formalin-fixed, paraffin embedded tissue sections were deparaffinised in xylene and rehydrated through descending concentrations of ethanol before antigen retrieval in a pressure cooker for 2 min at pH 6.0 in 10 mmol/L citrate buffer.
Endogenous peroxidase activity was quenched in 0.3% H$_2$O$_2$. Sections were incubated with primary antibody, under the conditions detailed in Table 6. Detection was with ImmPRESS HRP polymer-based system and visualisation was achieved using ImmPACT DAB (Vector Laboratories, Peterboroh, UK). Samples were counterstained with Gill 2 Haematoxylin (Thermo Shandon, Runcorn, UK) before brief immersion in acid alcohol and dehydration through ascending concentrations of ethanol, clearing in xylene and mounting in synthetic resin (Consul Mount, Thermo Fisher, Runcorn, UK).

As a negative control, non-immune mouse or rabbit IgG (Vector Laboratories, Peterborough, UK) at 3 µg/mL replaced the primary antibody.

| Antibody | Clone   | Type and Host Species | Supplier | Dilution | Incubation |
|----------|---------|-----------------------|----------|----------|------------|
| NOP10    | EPR8586 | Rabbit monoclonal     | Abcam (Cambridge, UK) | 1/2000  | O/N 4°C    |
| NHP2     | H-9     | Mouse monoclonal      | Santa Cruz Biotechnology(Insight Bio, Wembley, UK) | 1/8000  | O/N 4°C    |
| NOP56    | CL2603  | Mouse monoclonal      | Abcam (Cambridge, UK) | 1/1000  | O/N 4°C    |
| TERF1    | TRF-78  | Mouse monoclonal      | Santa Cruz Biotechnology(Insight Bio, Wembley, UK) | 1/50    | O/N 4°C    |
| TERF2    | B5      | Mouse monoclonal      | Santa Cruz Biotechnology(Insight Bio, Wembley, UK) | 1/200   | O/N 4°C    |
| TERF2IP  | 4C8/1   | Mouse monoclonal      | Santa Cruz Biotechnology(Insight Bio, Wembley, UK) | 1/100   | O/N 4°C    |
| Ki67     | MM1     | Mouse monoclonal      | Leica (Milton Keynes, UK) | 1/200   | O/N 4°C    |
| ERα      | 6F11    | Mouse monoclonal      | Leica (Milton Keynes, UK) | 1/50    | 2 h RT     |
| ERβ      | PPG5/10 | Mouse monoclonal      | Abcam (Cambridge, UK) | 1/50    | O/N 4°C    |
| PR       | Pgr636  | Mouse monoclonal      | DAKO (Ely, UK) | 1/1000  | 1 h RT     |
| AR       | AR441   | Mouse monoclonal      | DAKO (Ely, UK) | 1/75    | O/N 4°C    |

Nuclear staining of endometrial glands was analysed semi-quantitatively using a modified Quickscore estimated under light microscopy at a magnification of 20×. As NOP56 is a nucleolar protein, only the nucleolar staining was scored and this was performed at a magnification of 60×. Staining intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong) was multiplied by percentage of positive cells (0–25% = 1, 25–50% = 2, 51–75% = 3, >75% = 4) to obtain a final score out of 12. A subset of samples was double-scored independently by a gynaecological pathologist; allocated scores were compared then scorers met to agree on discrepancies.

Available data for the four steroid receptors (ERα, ERβ, PR and AR) expression and cell proliferation marker Ki67 was correlated with study data. The immunostaining for steroid receptors was also assessed semi-quantitatively using a four-tiered Liverpool Endometrial Steroid Quickscore and the Ki67 proliferative index was evaluated as the percentage of immunopositive cells, of any intensity [78,79].

4.4. Statistical Analysis

Relative transcript expression was calculated by the ΔΔCT method, relative to the three reference genes, PPIA, IPO8 and MRPL19 and normalised to the Ishikawa cell line control, using Bio-Rad CFX manager (Bio-Rad, Hertfordshire, UK).

GraphPad Prism 5 (GraphPad Software; San Diego, CA, USA) was used for all statistical analysis. The non-parametric one-way ANOVA Kruskal–Wallis was used to examine multiple groups. The non-parametric Mann–Whitney U-test was also used to analyse differences between two groups. ECs were categorized according to protein expression scores (high or low abundance) to compare the expression in relation to survival. Several quick score cut-off points were tested (starting with the median) to identify the expression cut-off that distinguished the group with the worst outcomes [79]. Out of the tested cut-offs,
the one showing the best categorization was used and is displayed on the graphs in Figure 5. The Mantel-Cox test was used for survival curve comparisons. Spearman’s rank correlation co-efficient was calculated to measure associations between proteins of interest, Ki67 and steroid receptors. For all comparisons, a $p$-value of $<0.05$ was considered significant.

5. Conclusions
In summary, we present a comprehensive description of six different TTAPs in the healthy human endometrium, and in EC samples. In this study we report upregulation of NOP10 and downregulation of NHP2, TERF2 and TERF2IP in EC relative to healthy post-menopausal endometrium. Further to this, IHC analysis highlighted NHP2, TERF2 and TERF2IP immunoscores were also reduced in EC. Our results indicate TTAPs NHP2, TERF2 and TERF2IP have potential as a future biomarker in endometrial carcinogenesis, that can be detected utilising affordable and widely used laboratory techniques. Survival analysis implies NHP2 protein levels may also carry prognostic significance in cancer associated survival, with improved survival in EC with high abundance of NHP2. Our data will inform researchers areas in telomerase and telomere biology to focus future research in EC. Further evaluation of the prognostic and functional role of the examined proteins is warranted to develop novel treatment strategies in EC.

Supplementary Materials: Supplementary materials can be found at https://www.mdpi.com/article/10.3390/ijms23020626/s1.

Author Contributions: Conceptualization, D.K.H.; methodology, J.D., L.B., A.B., R.A. and D.K.H.; formal analysis, L.B., B.R., E.T., A.B., R.A. and J.D.; resources, D.K.H.; writing—original draft preparation, L.B., J.D., D.K.H.; writing—review and editing, L.B., B.R., E.T., A.B., R.A., J.D., D.K.H.; supervision, J.D., D.K.H.; funding acquisition, D.K.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the University of Liverpool (MRes studentships L.B, E.T., A.B.), Liverpool Women’s Hospital NHS Trust (Research and development J.D.), and Higher Committee for Education Development in Iraq (R.A.). DKH was supported by Wellbeing of Women’s grants RG1487 and RG2137, Northwest Cancer Research RDG2021.18.

Institutional Review Board Statement: The study was performed in accordance with the Declaration of Helsinki. The Liverpool and Cambridge Adult Research Ethics Committees (LREC 09/H1005/55, 11/H1005/4 and CREC 10/H0308/75) approved the study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data is contained within the article or Supplementary Material.

Acknowledgments: The authors would like to thank all patients who kindly participated and donated endometrial tissue to this study. The authors also gratefully acknowledge the support from the technical and laboratory staff at the Liverpool Women’s NHS Foundation Trust.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| TTAPs        | Telomere and telomerase associated proteins |
| TCGA         | The Cancer Genome Atlas |
| EC           | Endometrial cancer |
| qPCR         | Quantitative polymerase chain reaction |
| IHC          | Immunohistochemistry |
References

1. Amant, F.; Moerman, P.; Neven, P.; Timmerman, D.; Van Limbergen, E.; Vergote, I. Endometrial cancer. *Lancet* 2005, *366*, 491–505. [CrossRef]
2. Cancer Research UK Uterine Cancer Statistics. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer (accessed on 10 October 2021).
3. Fung-Kee-Fung, M.; Dodge, J.; Elit, L.; Lukka, H.; Chambers, A.; Oliver, T. Follow-up after primary therapy for endometrial cancer: A systematic review. *Gynecol. Oncol.* 2006, *101*, 520–529. [CrossRef]
4. Adishesh, M.; Hapangama, D.K. Enriching Personalized Endometrial Cancer Research with the Harmonization of Biobanking Standards. *Cancers* 2019, *11*, 1734. [CrossRef] [PubMed]
5. Meyne, J.; Ratliff, R.L.; Moyzis, R.K. Conservation of the human telomere sequence (TTAGGG)n among vertebrates. *Proc. Natl. Acad. Sci. USA* 1989, *86*, 7049–7053. [CrossRef] [PubMed]
6. Palm, W.; de Lange, T. How Shelterin Protects Mammalian Telomeres. *Annu. Rev. Genet.* 2008, *42*, 301–334. [CrossRef] [PubMed]
7. Henderson, E.R.; Blackburn, E.H. An overhanging 3′ terminus is a conserved feature of telomeres. *Mol. Cell. Biol.* 1989, *9*, [CrossRef]
8. Maríon, R.M.; Montero, J.J.; López de Silanes, I.; Graña-Castro, O.; Martínez, P.; Schoeftner, S.; Palacios-Fábrega, J.A.; Blasco, M.A. TERRA regula the transcriptional landscape of pluripotent cells through TRF1-dependent recruitment of PRC2. eLife 2019, *8*, e44656. [CrossRef]
9. Adishesh, M.; Alnafakh, R.; Baird, D.M.; Jones, R.E.; Simon, S.; Button, L.; Kamal, A.M.; Kirwan, J.; Decruze, S.B.; Drury, J.; et al. Human Endometrial Carcinogenesis Is Associated with Significant Reduction in Non-Coding RNA, TERRA. *Int. J. Mol. Sci.* 2020, *21*, 8686. [CrossRef]
10. Osterhage, J.L.; Friedman, K.L. Chromosome End Maintenance by Telomerase. *J. Biol. Chem.* 2009, *284*, 16061–16065. [CrossRef]
11. Shammas, M.A. Telomeres, lifestyle, cancer, and aging. *Curr. Opin. Clin. Nutr. Metab. Care* 2011, *14*, 28–34. [CrossRef]
12. Kong, C.M.; Lee, X.W.; Wang, X. Telomere shortening in human diseases. *FEBS J.* 2013, *280*, 3180–3193. [CrossRef] [PubMed]
13. Lingner, J.; Hughes, T.R.; Shevchenko, A.; Mann, M.; Lundblad, V.; Cech, T.R. Reverse Transcriptase Motifs in the Catalytic Subunit of Telomerase. *Science* 1997, *276*, 561–567. [CrossRef]
14. Venteicher, A.S.; Abreu, E.B.; Meng, Z.; McCann, K.E.; Terrs, R.M.; Veenstra, T.D.; Terns, M.P.; Artandi, S.E. A Human Telomerase Holoenzyme Protein Required for Cajal Body Localization and Telomere Synthesis. *Science* 2009, *323*, 644–648. [CrossRef]
15. Blackburn, E.H.; Collins, K. Telomerase: An RNP Enzyme Synthesizes DNA. *Cold Spring Harb. Perspect. Biol.* 2010, *3*, a003558. [CrossRef]
16. Mitchell, J.R.; Cheng, J.; Collins, K. A Box H/ACA Small Nucleolar RNA-Like Domain at the Human Telomerase RNA 3′ End. *Mol. Cell. Biol.* 1999, *19*, 567–576. [CrossRef]
17. Pogacić, V.; Dragon, F.; Filipowicz, W. Human H/ACA Small Nucleolar RNPs and Telomerase Share Evolutionarily Conserved Proteins NHP2 and NOP10. *Mol. Cell. Biol.* 2000, *20*, 9028–9040. [CrossRef]
18. Egan, E.D.; Collins, K. Specificity and Stoichiometry of Subunit Interactions in the Human Telomerase Holoenzyme Assembled In Vivo. *Mol. Cell. Biol.* 2010, *30*, 2775–2786. [CrossRef] [PubMed]
19. Meier, U.T. The many facets of H/ACA ribonucleoproteins. *Chromosoma* 2005, *114*, 1–14. [CrossRef]
20. Dez, C.; Henras, A.; Faucon, B.; Lafontaine, D.; Caizergues-Ferrer, M.; Henry, Y. Stable expression in yeast of the mature form of human telomerase RNA depends on its association with the box H/ACA small nucleolar RNP proteins Cbf5p, Nhp2p and Nop10p. *Nucleic Acids Res.* 2001, *29*, 598–603. [CrossRef]
21. Knox, A.A.; McKeegan, K.S.; Debieux, C.M.; Traylor, A.; Richardson, H.; Watkins, N.J. A Weak C′ Box Renders U3 snoRNA Levels Dependent on hU3-55K Binding. *Mol. Cell. Biol.* 2011, *31*, 2404–2412. [CrossRef] [PubMed]
22. Gautier, T.; Bergès, T.; Tollervey, D.; Hurt, E. Nucleolar KKE/D repeat proteins Nop56p and Nop58p interact with Nop1p and are required for ribosome biogenesis. *Mol. Cell. Biol.* 1997, *17*, 7088–7098. [CrossRef]
23. Lechertier, T.; Grob, A.; Hernandez-Verdun, D.; Roussel, P. Fibriilin and Nop56 interact before being co-assembled in box C/D snoRNPs. *Exp. Cell Res.* 2009, *315*, 928–942. [CrossRef]
24. Cowling, V.H.; Turner, S.A.; Cole, M.D. Burkitt’s lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis. *Oncogene* 2014, *33*, 3519–3527. [CrossRef]
25. STRING: Functional Protein Association Networks. Available online: https://string-db.org/ (accessed on 14 June 2020).
26. Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019, *47*, D607–D613. [CrossRef]
27. Ungar, L.; Yosef, N.; Sela, Y.; Sharan, R.; Ruppin, E.; Kupiec, M. A genome-wide screen for essential yeast genes that affect telomere length maintenance. *Nucleic Acids Res.* 2009, *37*, 3840–3849. [CrossRef]
28. Brien, T.P.; Kallakury, B.V.; Lowry, C.V.; A Ambros, R.; Muraca, P.J.; Malfetano, J.H.; Ross, J.S. Telomerase activity in benign endometrium and endometrial carcinoma. *Cancer Res.* 1997, *57*, 2760–2764. [PubMed]
29. Lehner, R.; Enomoto, T.; McGregor, J.A.; Shroyer, A.L.; Haugen, B.R.; Pugazhenthi, U.; Shroyer, K.R. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. *Gynecol. Oncol.* 2002, *84*, 120–125. [CrossRef] [PubMed]
30. Sfeir, A.; Kosiyatrakul, S.T.; Hockemeyer, D.; MaRae, S.L.; Karlsseder, J.; Schildkraut, C.L.; de Lange, T. Mammalian Telomeres Resemble Fragile Sites and Require TRF1 for Efficient Replication. *Cell* 2009, 138, 90–103. [CrossRef] [PubMed]
31. Van Steensel, B.; de Lange, T. Control of telomere length by the human telomeric protein TRF1. *Nature* 1997, 385, 740–743. [CrossRef]
32. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. *Cell* 2011, 144, 646–674. [CrossRef]
33. Cesare, A.J.; Reddel, R.R. Alternative lengthening of telomeres: Models, mechanisms and implications. *Nat. Rev. Genet.* 2010, 11, 319–330. [CrossRef]
34. Kim, N.W.; Piaytsezk, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L.; Coviello, G.M.; Wright, W.E.; Weinrich, S.L.; Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994, 266, 2011–2015. [CrossRef]
35. Gul, I.; Dundar, O.; Bodur, S.; Tunca, Y.; Tutuncu, L. The Status of Telomerase Enzyme Activity in Benign and Malignant J. Biol. Chem. [CrossRef]
36. Alnafakh, R.A.A.; Adishesh, M.; Button, L.; Saretzki, G.; Hapangama, D.K. Telomerase and Telomeres in Endometrial Cancer. [CrossRef]
37. Valentijn, A.J.; Saretzki, G.; Tempest, N.; Critchley, H.O.D.; Hapangama, D.K. Human endometrial epithelial telomerase is important for epithelial proliferation and glandular formation with potential implications in endometriosis. *Hum. Reprod.* 2015, 30, 2816–2828. [CrossRef] [PubMed]
38. Tanaka, M.; Kyo, S.; Takakura, M.; Kanaya, T.; Sagawa, T.; Yamashita, K.; Okada, Y.; Hiyama, E.; Inoue, M. Expression of Telomerase Activity in Human Endometrium Is Localized to Epithelial Glandular Cells and Regulated in a Menstrual Phase-Dependent Manner Correlated with Cell Proliferation. *Am. J. Pathol.* 1998, 153, 1985–1991. [CrossRef]
39. Kyo, S.; Takakura, M.; Kohama, T.; Inoue, M. Telomerase activity in human endometrium. *Cancer Res.* 1997, 57, 610–614. [CrossRef]
40. Gul, I.; Dundar, O.; Bodur, S.; Tunca, Y.; Tutuncu, L. The Status of Telomerase Enzyme Activity in Benign and Malignant Gynaecologic Pathologies. *Balk. Med. J.* 2013, 30, 287–292. [CrossRef]
41. Uhlen, M.; Zhang, C.; Lee, S.; Jöststedt, E.; Fagerberg, L.; Bidkhori, G.; Benfeitas, R.; Arif, M.; Liu, Z.; Edfors, F; et al. A pathology atlas of the human cancer transcriptome. *Science* 2017, 357, 2507. [CrossRef]
42. Bradfield, A.; Button, L.; Drury, J.; Green, D.C.; Hill, C.J.; Hapangama, D.K. Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer. *Methods Protoc.* 2020, 3, 63. [CrossRef]
43. Kandoth, C.; Schultz, N.; Cherniack, A.D.; Akbani, R.; Liu, Y.; Shen, H.; Robertson, A.G.; Pashtan, I.; Shen, R.; Benz, C.C.; et al. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013, 497, 67–73. [CrossRef]
44. Alnafakh, R.; Saretzki, G.; Midgley, A.; Flynn, J.; Kamal, A.M.; Dobson, L.; Natarajan, P.; Stringfellow, H.; Martin-Hirsch, P.; Decruze, S.B.; et al. Aberrant Dyskerin Expression Is Related to Proliferation and Poor Survival in Endometrial Cancers. *Cancers* 2021, 13, 273. [CrossRef]
45. The Human Protein Atlas. GAR1—ENDOMETRIAL CANCER—Interactive Survival Scatter Plot & Survival Analysis. Available online: https://www.proteinatlas.org/ENSG00000109534-GAR1/pathology/endometrial+cancer (accessed on 24 December 2021).
46. Szklarczyk, D.; Gable, A.L.; Nastou, K.C.; Lyon, D.; Kirsch, R.; Pyysalo, S.; Doncheva, N.T.; Legeay, M.; Fang, T.; Bork, P.; et al. The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.* 2021, 49, D605–D612. [CrossRef]
47. Liu, F.; Pu, X.-Y.; Huang, S.-G.; Xiang, G.-M.; Jiang, D.-N.; Hou, G.; Huang, D.-N. Expression of hPOT1 in HeLa cells and the probability of gene variation of hpot1 Exon14 in endometrial cancer are much higher than in other cancers. *Asian Pac. J. Cancer Prev.* 2016, 17, 25–32. [CrossRef]
48. De Lange, T. What I got wrong about shelterin. *J. Biol. Chem.* 2018, 293, 10453–10456. [CrossRef]
49. Dos Santos, P.C.; Panero, J.; Stanganelli, C.; Palau Nagore, V.; Stella, F.; Bezares, R.; Slavutsky, I. Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia. *PLoS ONE* 2017, 12, e0179883. [CrossRef]
50. Elsharawy, K.A.; Alhobiti, M.; Mohammed, O.J.; Alojhan, A.I.; Toss, M.S.; Green, A.R.; Rakha, E.A. Nuclear protein 10 (NOP10) predicts poor prognosis for invasive breast cancer. *Breast Cancer Res. Treat.* 2020, 185, 615–627. [CrossRef] [PubMed]
51. Kim, M.S.; Kim, S.S.; Yao, N.J.; Lee, S.H. Expressional analysis of NOLA1, NOLA2, NOLA3 and DKC1, the core proteins in H/ACA ribonucleoproteins, in gastric and colorectal cancers. *Pathology* 2012, 44, 576–577. [CrossRef] [PubMed]
52. Witkowska, A.; Gumprecht, J.; Głogowska-Ligus, J.; Wysytkowych, G.; Owczarek, A.; Stachowicz, M.; Bocianska, A.; Nowakowska-Zajdel, E.; Mazurek, U. Expression profile of significant immortalization genes in colon cancer. *Int. J. Mol. Med.* 2011, 28, 90–103. [PubMed]
Kamal, A.M.; Bulmer, J.N.; DeCruze, S.B.; Stringfellow, H.F.; Martin-Hirsch, P.; Hapangama, D.K. Androgen receptors are
Bejarano, L.; Schuhmacher, A.J.; M.
Lin, X.; Gu, J.; Lu, C.; Spitz, M.R.; Wu, X. Expression of Telomere-Associated Genes as Prognostic Markers for Overall Survival in
Hu, J.; Sun, L.; Zhang, C.; Zhou, X.L. Expression of telomeric repeat binding factor 1 protein in nonsmall cell lung cancer with
Teo, H.; Ghosh, S.; Luesch, H.; Ghosh, A.; Wong, E.T.; Malik, N.; Orth, A.; De Jesus, P.; Perry, A.S.; Oliver, J.D.; et al. Telomere-
Yang, Y.; Ye, C.; Wang, L.; An, G.; Tian, Z.; Meng, L.; Qu, L.; Lian, S.; Shou, C. Repressor activator protein 1–promoted colorectal
Kustatscher, G.; Grabowski, P.; Schrader, T.A.; Passmore, J.B.; Schrader, M.; Rappsilber, J. Co-regulation map of the human
Marcel, V.; Catez, F.; Berger, C.M.; Perrial, E.; Plesa, A.; Thomas, X.; Mattei, E.; Hayette, S.; Saintigny, P.; Bouvet, P.; et al. Expression
Kustatscher, G.; Grabowski, P.; Schrader, T.A.; Passmore, J.B.; Schrader, M.; Rappsilber, J. Co-regulation map of the human
Hu, J.; Sun, L.; Zhang, C.; Zhou, X.L. Expression of telomeric repeat binding factor 1 protein in nonsmall cell lung cancer with human telomerase reverse transcriptase positive. Int. J. Surg. Pathol. 2008, 16, 414–418. [CrossRef]
Lin, X.; Gu, J.; Lu, C.; Spitz, M.R.; Wu, X. Expression of Telomere-Associated Genes as Prognostic Markers for Overall Survival in Patients with Non–Small Cell Lung Cancer. Clin. Cancer Res. 2006, 12, 5720–5725. [CrossRef]
Yamada, M.; Tsui, N.; Nakamura, M.; Moriai, R.; Kobayashi, D.; Yagihashi, A.; Watanabe, N. Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers. Anticancer Res. 2003, 22, 3303–3307.
Miyachi, K.; Fujita, M.; Tanaka, N.; Sasaki, K.; Sunagawa, M. Correlation between telomerase activity and telomeric-repeat binding factors in gastric cancer. J. Exp. Clin. Cancer Res. 2002, 21, 269–275.
Bejarano, L.; Schuhmacher, A.J.; Méndez, M.; Megias, D.; Blanco-Aparicio, C.; Martínez, S.; Pastor, J.; Squaritó, M.; Blasco, M.A. Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts. Cancer Cell 2017, 32, 590–607.e4. [CrossRef]
Wang, Z.; Wu, X. Abnormal function of telomere protein TRF2 induces cell cycle mutation and the effects of environmental tumor-promoting factors (Review). Oncol. Rep. 2021, 46, 1–20. [CrossRef]
Wu, M.; Lin, Z.; Li, X.; Xin, X.; An, J.; Zheng, Q.; Yang, Y.; Lu, D. HULC cooperates with MALAT1 to aggravate liver cancer stem cells growth through telomere repeat-binding factor 2. Sci. Rep. 2016, 6, 36045. [CrossRef] [PubMed]
Özden, S.; Tiber, P.M.; Ozgen, Z.; Ozyurt, H.; Serakinci, N.; Orun, O. Expression of TRF2 and its prognostic relevance in advanced stage cervical cancer patients. Biol. Res. 2014, 47, 61. [CrossRef]
Teo, H.; Ghosh, S.; Luesch, H.; Ghosh, A.; Wong, E.T.; Malik, N.; Orth, A.; De Jesus, P.; Perry, A.S.; Oliver, J.D.; et al. Telomere-independent Rap1 is an IKK adaptor and regulates NF-κB-dependent gene expression. Nat. Cell Biol. 2010, 12, 758–767. [CrossRef]
Yang, Y.; Ye, C.; Wang, L.; An, G.; Tian, Z.; Meng, L.; Qu, L.; Lian, S.; Shou, C. Repressor activator protein 1–promoted colorectal cell migration is associated with the regulation of Vimentin. Tumor Biol. 2017, 39. [CrossRef]
Adishesh, M.; Fyson, A.; Decruze, S.B.; Kirwan, J.; ENITEC Consortium; Werner, H.M.J.; Hapangama, D.K. Harmonisation of biobanking standards in endometrial cancer research. Br. J. Cancer 2015, 117, 485–493. [CrossRef] [PubMed]
Alnafakh, R.; Choi, F.; Bradfield, A.; Adishesh, M.; Saretzki, G.; Hapangama, D.K. Endometriosis Is Associated with a Significant Increase in hTERC and Altered Telomere/Telomerase Associated Genes in the Eutopic Endometrium, an Ex Vivo and In Silico Study. Biomedicines 2020, 8, 588. [CrossRef]
Maclean, A.; Bunni, E.; Makrydima, S.; Wittington, A.; Kamal, A.M.; Valentijn, A.J.; Hapangama, D.K. Fallopian tube epithelial cells express androgen receptor and have a distinct hormonal responsiveness when compared with endometrial epithelium. Hum. Reprod. 2020, 35, 2097–2106. [CrossRef]
Tempest, N.; Jansen, M.; Baker, A.M.; Hill, C.J.; Hale, M.; Magee, D.; Treanor, D.; Wright, N.A.; Hapangama, D.K. Histological 3D reconstruction and in vivo lineage tracing of the human endometrium. J. Pathol. 2020, 251, 440–451. [CrossRef] [PubMed]
Hapangama, D.K.; Drury, J.; Da Silva, L.; Al-Lamee, H.; Earp, A.; Valentijn, A.J.; Edirisinhe, D.P.; Murray, P.A.; Fazleabas, A.T.; Gargett, C.E. Abnormally located SSEA1+/SOX9+ endometrial epithelial cells with a basalis-like phenotype in the eutopic functionalis layer may play a role in the pathogenesis of endometriosis. Hum. Reprod. 2019, 34, 56–68. [CrossRef]
Kamal, A.M.; Bulmer, J.N.; DeCruze, S.B.; Stringfellow, H.F.; Martin-Hirsch, P.; Hapangama, D.K. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br. J. Cancer 2016, 114, 688–696. [CrossRef] [PubMed]
Kamal, A.; Valentijn, A.; Barraclough, R.; Rudland, P.; Rahmatalla, N.; Martin-Hirsch, P.; Stringfellow, H.; Decruze, S.B.; Hapangama, D.K. High AGR2 protein is a feature of low grade endometrial cancer cells. Oncotarget 2018, 9, 31459–31472. [CrossRef] [PubMed]